Lund, 6 April, 2017
Enzymatica - publication of the annual report 2016
Enzymatica announces today that the annual report 2016 is available on the company's web site
www.enzymatica.se. The annual report is produced in Swedish. A brief English version of the annual report is available on the English version of the website.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: email@example.com
Jörgen Rexö, VP Legal & Communications Enzymatica
Tel: 0708-19 22 82 | E-post: firstname.lastname@example.org
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on eight markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser Bankaktiebolag.